Navigation Links
September is National Pain Awareness Month
Date:9/28/2007

SEVERE CHRONIC PAIN - ONE OF COUNTRY'S GREAT HIDDEN HEALTH CRISES - 70

MILLION AMERICANS SUFFER WITHOUT RELIEF Treatment Developed from Sea Snail Offers Relief for Severe Chronic Pain

Sufferers

NEW YORK, Sept. 28 /PRNewswire/ -- The under-treatment of pain is one of the most important public health issues facing the United States today, impacting the lives of an estimated one in three Americans, according to the National Pain Foundation. Unfortunately, many patients who suffer from severe chronic pain do not experience long-term relief from available treatments and key aspects of their daily lives -- including normal physical activity, employment, relationships and a multitude of other capacities -- are often severely compromised.(1)

However, hope exists for those who are suffering in the form of a sea snail. Researchers at Elan Pharmaceuticals, Inc., a wholly-owned subsidiary of Elan Corporation, plc, have harnessed the venom of the Conus magus sea snail into a non-narcotic alternative to traditional pain medications. PRIALT(R) (ziconotide intrathecal infusion), a synthetic form of a naturally occurring peptide, circumvents concerns over addiction and safety linked to opioid use.

"Chronic pain disrupts an individual's life and can add tremendous physical, emotional and economic burden," said Mary Pat Aardrup, executive director, National Pain Foundation. "Chronic pain is one of the great hidden crises of our time, made all the more urgent by the fact that treatment is often limited mainly to opioid medications that may be inadequate or inappropriate for many patients. PRIALT is an important chapter in the management of severe chronic pain that warrants intrathecal therapy."

Physicians and patients nationwide are discovering the pain-relieving capabilities of PRIALT. Dawn Campbell endured 32 surgeries to relieve severe pain in her bladder, back and legs, including removal of her
'/>"/>

SOURCE PRIALT
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
7. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
8. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Pharma Major Lupin Limited today announced ... Russia subject to certain closing conditions. ... which recorded RUB 765 billion in sales, placing it as ... in 2014 (IMS Health). For over a decade, Russian pharmaceutical ... this trend, projecting Russia to be ...
(Date:7/2/2015)... , June 25, 2015 ... has announced the addition of the ... Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive Landscape" ... 2015 New Frontiers in Clinical Chemistry and ... is a new seven-country strategic analysis of ...
(Date:7/2/2015)... , July 2, 2015  The Commission ... agreement with ASHP, an organization that represents pharmacists ... a provider of continuing education for recertification of ... track of geriatric programs for this purpose.  ASHP ... as authorized providers for the CCGP Professional Development ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2Commission for Certification in Geriatric Pharmacy Adds ASHP as Professional Development Program Provider 2
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
... of Gastroenterology Annual ... ... two Phase 3,studies presented at the American College of Gastroenterology Annual,Scientific ... rates than lansoprazole among patients with more,severe grades of erosive esophagitis ...
Cached Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... The ZAC ... the 2015 swim season with important lessons on how to stay water safe with ... Who Couldn’t, Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s water safety ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... announced today that it has reached an agreement to acquire eRubbermaid.com, an ... largest distributor of Rubbermaid Commercial Products on the web today. ...
(Date:7/2/2015)... PA (PRWEB) , ... July 02, 2015 , ... ... Vaccine Research (CVR) recently received nearly $4 million through five federal grants ... develop vaccines and therapies against the deadly diseases. , The research will ...
(Date:7/2/2015)... ... 02, 2015 , ... B. E. Smith, the only full-service ... a national chief operating officer recruitment for Nicklaus Children’s Hospital in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... Nutraceutical company, is announcing with their launch an intention to partner with companies ... health solutions on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined ...
Breaking Medicine News(10 mins):Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3
... -- A NewYork-Presbyterian Hospital/Weill Cornell Medical Center review of almost ... therapy reported in a widely publicized study was lost in ... The researchers report in the May ... Medical Association, that medical therapy given to patients who ...
... (HealthDay News) -- Shortages of anesthetics are rampant across the ... The findings revealed that more than 90 percent of ... States) are experiencing a shortage of at least one drug. ... encountered a similar problem, the poll by the American Society ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... -- best known as Tylenol -- regularly for some ... for developing certain blood cancers, University of Washington researchers ... the association between over-the-counter painkillers or nonsteroidal anti-inflammatory drugs ...
... HealthDay Reporter , TUESDAY, May 10 (HealthDay News) -- ... scan the inside of the colon may one day be ... from Japan,s Osaka Medical College have developed a "self-propelled capsule ... through the colon via remote control and a magnetic field, ...
... from the UCLA Center for Health Policy Research, the majority ... health insurance coverage initiatives in California in 2014 are also ... health services: men, singles and those of working age. ... the federal Patient Protection and Affordable Care Act (ACA), up ...
... adhere to medications for their chronic health problems than ... risk of poor health, according to a new RAND ... a wide array of chronic illnesses such as diabetes ... being non-adherent with their medications compared to patients who ...
Cached Medicine News:Health News:Lessons from major heart trial need implementation 2Health News:Lessons from major heart trial need implementation 3Health News:Lessons from major heart trial need implementation 4Health News:Shortage of Anesthetics Reported 2Health News:Chronic Tylenol Use May Be Linked to Blood Cancer, Study Suggests 2Health News:Chronic Tylenol Use May Be Linked to Blood Cancer, Study Suggests 3Health News:A Capsule Camera Instead of a Colonoscopy? 2Health News:A Capsule Camera Instead of a Colonoscopy? 3Health News:2 new studies describe likely beneficiaries of health care reform in California 2Health News:2 new studies describe likely beneficiaries of health care reform in California 3Health News:Depression associated with poor medication adherence in patients with chronic illnesses 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: